Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
University Department of Medical Oncology, Cancer and Haematology Centre, Churchill Hospital, Headington OX3 7LJ, UK.
This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs).
Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1-14 of 3-week cycles.
Treatment was safe and well tolerated. Common toxicities were diarrhoea and fatigue.
The study provides evidence to support the use of capecitabine as a substitute for infusional 5FU in the management of NETs.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on